Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560792 | 1.00 | HSD17B10 (0.39) | HSD17B10SLC6A9MGLLTSHRS1PR1 | |
| SCHEMBL17057486 | 0.95 | HSD17B10 (0.36) | HSD17B10SLC6A9MGLLTSHRS1PR1 | |
| SCHEMBL17053358 | 0.95 | HSD17B10 (0.36) | HSD17B10SLC6A9MGLLTSHRS1PR1 | |
| SCHEMBL12238070 | 0.92 | LMNA (0.36) | HSD17B10TSHRALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL437100 | 0.92 | LMNA (0.36) | HSD17B10TSHRALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL12038457 | 0.91 | CHRM5 (0.35) | HSD17B10SLC6A9TSHR | |
| SCHEMBL14522328 | 0.91 | CHRM5 (0.35) | HSD17B10SLC6A9TSHR | |
| SCHEMBL25039379 | 0.90 | HSD17B10 (0.33) | HSD17B10SLC6A9 | |
| SCHEMBL23662688 | 0.90 | SLC6A9 (0.33) | HSD17B10SLC6A9TSHR | |
| SCHEMBL12231841 | 0.90 | CHRM5 (0.34) | HSD17B10SLC6A9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118490641-A | Preparation method and application of macromolecular metal beta-lactamase inhibitor | 山西省人民医院 | 2024-08-16 | — | — | CN | claimed |
| CN-117924427-A | Al (aluminum) alloy18F-labeled antibacterial peptide UBI 29-41 derivative and preparation method and application thereof | 北京师范大学 | 2024-04-26 | — | — | CN | claimed |
| CN-117653755-A | Tumor diagnosis molecular imaging probe based on amino acid metabolic pathway and preparation method and application thereof | 中国人民解放军海军军医大学第一附属医院 | 2024-03-08 | — | — | CN | claimed |
| CN-117338961-A | PD-L1 targeting molecular probe and preparation method and application thereof | 江南大学 | 2024-01-05 | — | — | CN | claimed |
| CN-114044804-A | TMTP1 polypeptide ligand radioactive probe and preparation method and application thereof | 厦门大学附属第一医院 | 2022-02-15 | — | — | CN | claimed |
| EP-4211146-B1 | SYNTHETIC CYCLIC PEPTIDE MIMETICS | UNIV BAR ILAN (IL) | 2026-05-20 | — | — | EP | disclosed |
| US-12616760-B2 | Synthetic cyclic peptide mimetics | BAR ILAN UNIVERSITY (IL) | 2026-05-05 | — | — | US | disclosed |
| US-20260055182-A1 | ANTI-L1-CAM ANTIBODIES AND THEIR USES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | CIS BIOPHARMA AG (CH) | 2026-02-26 | — | — | US | disclosed |
| US-12551583-B2 | Radiolabeled ligands for targeted PET/SPECT imaging and methods of their use | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| WO-2025238187-A1 | IMMUNOCONJUGATES TARGETING L1-CAM | CIS BIOPHARMA AG (CH) | 2025-11-20 | — | — | WO | disclosed |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| WO-2015121092-A1 | OPIOID RECEPTOR BINDING AGENTS AND USES THEREOF | VIB VZW (BE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015073678-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | ENDOCYTE, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073678-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | ENDOCYTE, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| EP-2855526-A1 | ANTI-MACROPHAGE MANNOSE RECEPTOR SINGLE VARIABLE DOMAINS FOR TARGETING AND IN VIVO IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | VIB vzw (BE) | 2015-04-08 | — | — | EP | disclosed |
| US-20150093336-A1 | ANTI-MACROPHAGE MANNOSE RECEPTOR SINGLE VARIABLE DOMAINS FOR TARGETING AND IN VIVO IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2015-04-02 | — | — | US | disclosed |
| WO-2014140376-A1 | ANTI-MACROPHAGE MANNOSE RECEPTOR SINGLE VARIABLE DOMAINS FOR USE IN CARDIOVASCULAR DISEASES | VIB VZW (BE) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014037419-A1 | IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS DIRECTED AGAINST CD74 AND USES DERIVED THEREOF | VIB VZW (BE) | 2014-03-13 | — | — | WO | disclosed |
| WO-2013174537-A1 | ANTI-MACROPHAGE MANNOSE RECEPTOR SINGLE VARIABLE DOMAINS FOR TARGETING AND IN VIVO IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | VIB VZW (BE) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | HSD17B10 2311/4885SLC6A9 3901/4885MGLL 3372/4885 |
| US-12616760-B2 | Synthetic cyclic peptide mimetics | TPX2, IAPP, HAX1 | HSD17B10 4795/4885SLC6A9 2877/4885MGLL 3692/4885 |
| US-20260055182-A1 | ANTI-L1-CAM ANTIBODIES AND THEIR USES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | IGSF11, L1CAM, CD74 | HSD17B10 4344/4885SLC6A9 4742/4885MGLL 4619/4885 |
| US-12551583-B2 | Radiolabeled ligands for targeted PET/SPECT imaging and methods of their use | SLC7A1, SLC38A7, SLC34A2 | HSD17B10 4769/4885SLC6A9 144/4885MGLL 1489/4885 |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | CA9, CA13, CA4 | HSD17B10 3729/4885SLC6A9 1379/4885MGLL 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.